ABSTRACT

In chronic obstructive pulmonary disease (COPD) are two clinical phenotypes, emphysema and chronic bronchitis. Phenotypes share clinical symptoms such as dyspnea and bronchial obstruction to air flow and an increase of innate immune cells (macrophages and neutrophils), the release of multiple inflammatory mediators (chemokines, cytokines, and growth factors), oxidative stress, increased extracellular matrix metalloproteinases (MMPs) in the airways and lung. Disease progression is associated with the presence of chronic inflammation and increased proteolytic activity of enzymes such as MMPs resulting in the degradation of elastin and collagen fibers in the walls of the alveoli and the lung’s extracellular matrix. Of particular interest for this review was to describe the role of MMPs, their participation in the development of COPD, both in the extracellular matrix destruction and abnormal lung remodeling damaged. Also mentioned genetic association studies of polymorphisms in MMPs type SNP in Caucasian populations such as the development and progression of COPD, and the importance of carrying out studies in Mexican mestizo population. The role of MMPs has also been known through animal models and knockout mice MMPs exposed to cigarette smoke. All these studies implicate MMPs as key mediators in the pathogenesis of COPD. Finally, the study of MMPs base allow for future therapies, potential therapeutic targets and disease treatments.

KEYWORDS

MMPs, COPD, polymorphism, SNP.

REFERENCES

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease NHLBI/WHO Workshop report. Rev. ed. 2013. Access date: 2013 June 3. Available from: http: //www.goldcopd. com

2. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932-946.

3. Organización Mundial de la Salud (OMS). Fecha de acceso: junio 3, 2013. Disponible en: http://www.who.int/es/

4. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004;56(4):515-548.

5. Barnes PJ. Chronic obstructive pulmonary disease: a growing but neglected global epidemic. PLoS Med 2007;4(5):e112.

6. Secretaría de Salud. Fecha de acceso: junio 3, 2013. Disponible en: http://www.salud.gob.mx/

7. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350(26):2645-2653.

8. Encuesta Nacional de Adicciones 2011. Fecha de acceso: junio 3, 2013. Disponible en: http://www.conadic.salud.gob.mx/pdfs/ENA_2011_DROGAS_ILICITAS_.pdf

9. Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 2009;360(26):2749-2757.

10. Strange C, Stoller JK, Sandhaus RA, Dickson R, Turino G. Results of a survey of patients with alpha-1 antitrypsin deficiency. Respiration 2006;73(2):185-190.

11. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999;160(5 Pt 2):S49-S52.

12. Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998; 157(6 Pt 1):1770-1778.

13. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011;378(9795):1015-1026.

14. Mahadeva R, Shapiro SD. Chronic obstructive pulmonary disease * 3: Experimental animal models of pulmonary emphysema. Thorax 2002;57(10):908-914.

15. Mannino DM. Chronic obstructive pulmonary disease: definition and epidemiology. Respir Care 2003;48(12):1185-1191.

16. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163(5):1256-1276.

17. Raherison C, Girodet PO. Epidemiology of COPD. Eur Respir Rev 2009;18(114):213-221.

18. National Center for Biotechnology Information (NCBI). Access date: 2013 June 3. Available from: http://www.ncbi.nlm.nih.gov/

19. Bode W, Grams F, Reinemer P, et al. The metzincin-superfamily of zinc-peptidases. Adv Exp Med Biol 1996;389:1-11.

20. Stocker W, Bode W. Structural features of a superfamily of zinc-endopeptidases: the metzincins. Curr Opin Struct Biol 1995;5(3):383-390.

21. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006 15;69(3):562-573.

22. Pathway Builder Tool 2.0 available from Protein Lounge, San Diego, CA, USA. Fecha de acceso: 3 de junio, 2013.

23. Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie 2005;87(3-4):249-263.

24. Lovett DH, Mahimkar R, Raffai RL, et al. A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One 2012;7(4):e34177.

25. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.

26. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 1991;266(21):14064-14071.

27. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995;270(10):5331-5338.

28. Seiki M. Membrane-type matrix metalloproteinases. APMIS 1999;107(1):137-143.

29. Cauwe B, Martens E, Van den Steen PE, et al. Adenylyl cyclase-associated protein-1/CAP1 as a biological target substrate of gelatinase B/MMP-9. Exp Cell Res 2008;314(15):2739-2749.

30. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2(3):161-174.

31. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477(1-2):267-283.

32. Löffek S, Schilling O, Franzke CW. Series “matrix metalloproteinases in lung health and disease”: Biological role of matrix metalloproteinases: a critical balance. Eur Respir J 2011;38(1):191-208.

33. Lagente V, Manoury B, Nénan S, Le Quément C, Martin-Chouly C, Boichot E. Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Braz J Med Biol Res 2005;38(10):1521-1530.

34. Moore CS, Crocker SJ. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 2012;180(1):12-16.

35. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010;20(3):161-168.

36. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115(Pt 19):3719-3727.

37. Delany AM, Jeffrey JJ, Rydziel S, Canalis E. Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms. J Biol Chem 1995;270(44):26607-26612.

38. Pendás AM, Balbín M, Llano E, Jiménez MG, López-Otín C. Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13). Genomics 1997;40(2):222-233.

39. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007;8(3):221-233.

40. Imai K, Dalal SS, Chen ES, et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med 2001;163(3 Pt 1):786-791.

41. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3(3):207-314.

42. Mira E, Lacalle RA, Buesa JM, et al. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci 2004;117(Pt 9):1847-1857.

43. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003;200(4):448-464.

44. Zanini A, Chetta A, Imperatori AS, Spanevello A, Olivieri D. The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respir Res 2010;11:132.

45. Nagira M, Imai T, Yoshida R, et al. A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells. Eur J Immunol 1998;28(5):1516-1523.

46. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997;151(4):1105-1113.

47. Alejandre-Alcázar MA, Michiels-Corsten M, Vicencio AG, et al. TGF-beta signaling is dynamically regulated during the alveolarization of rodent and human lungs. Dev Dyn 2008;237(1):259-269.

48. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15(1):61-75.

49. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000;14(2):163-176.

50. Vignola AM, Paganin F, Capieu L, et al. Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J 2004;24(6):910-917.

51. Culpitt SV, de Matos C, Russell RE, Donnelly LE, Rogers DF, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165(10):1371-1376.

52. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25(1):9-34.

53. Houghton AM, Grisolano JL, Baumann ML, et al. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res 2006;66(12):6149-6155.

54. Lambert E, Dassé E, Haye B, Petitfrère E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004;49(3):187-198.

55. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154(9):4379-4389.

56. Haas TL, Madri JA. Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc Med 1999;9(3-4):70-77.

57. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999;13(1):35-48.

58. Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 1997;272(50):31730-31737.

59. Holmbeck K, Bianco P, Chrysovergis K, Yamada S, Birkedal-Hansen H. MT1-MMP-dependent, apoptotic remodeling of unmineralized cartilage: a critical process in skeletal growth. J Cell Biol 2003;163(3):661-671.

60. Ohnishi K, Takagi M, Kurokawa Y, Satomi S, Konttinen YT. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998;78(9):1077-1087.

61. Finlay GA, O’Driscoll LR, Russell KJ, et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997;156(1):240-247.

62. Lim S1, Roche N, Oliver BG, Mattos W, Barnes PJ, Chung KF. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am J Respir Crit Care Med 2000;162(4 Pt 1):1355-1360.

63. Shapiro SD. Transgenic and gene-targeted mice as models for chronic obstructive pulmonary disease. Eur Respir J 2007;29(2):375-378.

64. Shapiro SD. Proteinases in chronic obstructive pulmonary disease. Biochem Soc Trans 2002;30(2):98-102.

65. Guerassimov A, Hoshino Y, Takubo Y, et al. The development of emphysema in cigarette smoke-exposed mice is strain dependent. Am J Respir Crit Care Med 2004;170(9):974-980.

66. Reynolds PR, Cosio MG, Hoidal JR. Cigarette smoke-induced Egr-1 upregulates proinflammatory cytokines in pulmonary epithelial cells. Am J Respir Cell Mol Biol 2006;35(3):314-319.

67. Goldklang MP, Marks SM, D’Armiento JM. Second hand smoke and COPD: lessons from animal studies. Front Physiol 2013;4:30.

68. Roycik MD, Fang X, Sang QX. A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates. Curr Pharm Des 2009;15(12):1295-1308.

69. Wright JL, Farmer SG, Churg A. Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Am J Respir Crit Care Med 2002;166(7):954-960.

70. Ismair MG1, Ries C, Lottspeich F, Zang C, Kolb HJ, Petrides PE. Autocrine regulation of matrix metalloproteinase-9 gene expression and secretion by tumor necrosis factor-alpha (TNF-alpha) in NB4 leukemic cells: specific involvement of TNF receptor type 1. Leukemia 1998;12(7):1136-1143.

71. Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol 2008;294(4):L612-631.

72. Wright JL, Tai H, Churg A. Vasoactive mediators and pulmonary hypertension after cigarette smoke exposure in the guinea pig. J Appl Physiol (1985). 2006;100(2):672-678.

73. Wright JL, Cosio M, Churg A. Animal models of chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2008;295(1):L1-L15.

74. Spond J, Chapman R, Fine J, et al. Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther 2001;14(2):157-164.

75. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 2002;99(11):7628-7633.

76. Stevenson CS, Coote K, Webster R, et al. Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect. Am J Physiol Lung Cell Mol Physiol 2005;288(3):L514-L522.

77. Shimajiri S, Arima N, Tanimoto A, et al. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett 1999;455(1-2):70-74.

78. Vlaykova T, Dimov D. Polymorphisms of matrix metalloproteinases (MMP) in COPD. Biotechnol & Biotechnol Eq 2012;26(1):111-120.

79. Haq I, Chappell S, Johnson SR, et al. Association of MMP-2 polymorphisms with severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a European population. BMC Med Genet 2010;11:7.

80. Rutter JL, Mitchell TI, Butticè G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998;58(23):5321-5325.

81. Affara M, Dunmore BJ, Sanders DA, Johnson N, Print CG, Charnock-Jones DS. MMP1 bimodal expression and differential response to inflammatory mediators is linked to promoter polymorphisms. BMC Genomics 2011;12:43.

82. Wallace AM, Mercer BA, He J, et al. Functional characterization of the matrix metalloproteinase-1 cigarette smoke-responsive region and association with the lung health study. Respir Res 2012;13:79.

83. Raza SL, Nehring LC, Shapiro SD, Cornelius LA. Proteinase-activated receptor-1 regulation of macrophage elastase (MMP-12) secretion by serine proteinases. J Biol Chem 2000;275(52):41243-41250.

84. Minematsu N, Nakamura H, Tateno H, Nakajima T, Yamaguchi K. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun 2001;289(1):116-119.

85. Zhou M, Huang SG, Wan HY, Li B, Deng WW, Li M. Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China. Chin Med J (Engl) 2004;117(10):1481-1484.

86. Jormsjö S, Ye S, Moritz J, et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000;86(9):998-1003.

87. Vecchio D, Arezzini B, Pecorelli A, Valacchi G, Martorana PA, Gardi C. Reactivity of mouse alveolar macrophages to cigarette smoke is strain dependent. Am J Physiol Lung Cell Mol Physiol 2010;298(5):L704-L713.

88. Bracke KR, D’hulst AI, Maes T, et al. Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice. J Immunol 2006;177(7):4350-4359.

89. Cheng SL, Wang HC, Yu CJ, et al. Prevention of elastase-induced emphysema in placenta growth factor knock-out mice. Respir Res 2009;10:115.

90. D’Armiento J, Dalal SS, Okada Y, Berg RA, Chada K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 1992;71(6):955-961.

91. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997;277(5334):2002-2004.

92. Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009;361(27):2599-2608.

93. Joos L, He JQ, Shepherdson MB, et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002;11(5):569-576.

94. van Diemen CC1, Postma DS, Siedlinski M, Blokstra A, Smit HA, Boezen HM. Genetic variation in TIMP1 but not MMPs predict excess FEV1 decline in two general population-based cohorts. Respir Res 2011;12:57.

95. Lee SY, Kim MJ, Kang HG, et al. Polymorphisms in matrix metalloproteinase-1, -9 and -12 genes and the risk of chronic obstructive pulmonary disease in a Korean population. Respiration 2010;80(2):133-138.